NOVATO, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (RARE) and Mereo BioPharma Group plc (MREO), today announced that the randomized, placebo-controlled Phase 3 portion of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback